Objective:To systematically evaluate the efficacy and safety of traditional Chinese medicine for regulating spleen and kidney.Methods:We developed a search strategy and then retrieved the database including CNKI,Wanfa...Objective:To systematically evaluate the efficacy and safety of traditional Chinese medicine for regulating spleen and kidney.Methods:We developed a search strategy and then retrieved the database including CNKI,Wanfang data knowledge service platform,VIP journals resource integration service platform,PubMed,Embasefor randomized controlled trial of regulating spleen and kidney traditional Chinese medicine compared with conventional western medicine in the treatment of chronic uric acid nephropathy.The search deadline was set to June 30,2020.For the included literature,we applied the cochrane collaboration network risk bias assessment tool to evaluate the methodological quality,and evaluated the level of evidence according to GRADE standards.Quantitative data was analyzed by RevMan5.3 software,and trial sequential analysis method was used to analyze its efficiency.Results:A total of 709 cases in 10 articles were included.Compared with the control group,the related traditional Chinese medicine group improved the effective rate[RR=1.45,95%CI(1.32,1.58)],reduced the level of UA[MD=-36.24,95%CI(-41.03,-31.45)],BUN[SMD=-1.27,95%CI(-1.47,-1.07)]and SCR[MD=-36.33,95%CI(-55.79,-16.87),P=0.0003],the difference between the two groups was statistically significant(P<0.05).There was no evidence that a significant adverse reaction occurred.The results of TSA analysis showed that the Chinese medicine group had definite evidence for improving the efficiency.According to the GRADE evaluation criteria,the efficiency,UA,BUN and SCR outcome indicators were extremely low-quality evidence.Conclusions:Traditional Chinese medicine for regulating spleen and kidney in the treatment of chronic uric acid nephropathy improved efficiency,reduced the level of UA,BUN,SCR.Meanwhile,the therapy was proved to be safe.Nevertheless,the conclusions need further high-quality evidence to support.展开更多
Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second high...Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second highest among peripheral nerve entrapment diseases,and it is one of the common clinical diseases.The theory of liver,spleen and kidney can guide the treatment of cubital tunnel syndrome with traditional Chinese medicine and acupuncture.By discussing the traditional Chinese medicine(TCM)pathogenesis and treatment principles of cubital tunnel syndrome,it provides modern medical theoretical support for TCM treatment of cubital tunnel syndrome.展开更多
Objective: To observe the acting pattern on the immune system by Kidney tonifying (KT) drugs. Methods: Three composite recipes were used on the 7- and 14-day corticosterone rat model to study the effect of recipes on...Objective: To observe the acting pattern on the immune system by Kidney tonifying (KT) drugs. Methods: Three composite recipes were used on the 7- and 14-day corticosterone rat model to study the effect of recipes on the different patterns of immuno-modulatory and neuro- endocrinological systems. Results:The immune system of Spleen Invigorating(SI) group was well protected in either 7- or 14-day experiments,with the SI recipe showing no effect on the neuroendocrine system. It suggested that SI recipe might have direct action on immune system. On the other hand, KT group with no effect on neuroendocrine-immune (NEI) system in 7-day experiment, but showed a remarkable protective effect of the whole NEI system in 14-day experiment. Conclusion: The results indicated that KT recipe acts on the neuroendocrine system first, and then influence the immune system. It means that the action took place through down pathway of NEI network.展开更多
目的探讨益气通络、健脾补肾法联合穴位贴敷在慢性阻塞性肺疾病(简称慢阻肺)稳定期患者中的应用效果。方法采用随机数字表法将于2020年1月—2021年12月在河北省张家口市中医院接受治疗的180例慢阻肺稳定期患者分为A组、B组和C组,各60例...目的探讨益气通络、健脾补肾法联合穴位贴敷在慢性阻塞性肺疾病(简称慢阻肺)稳定期患者中的应用效果。方法采用随机数字表法将于2020年1月—2021年12月在河北省张家口市中医院接受治疗的180例慢阻肺稳定期患者分为A组、B组和C组,各60例。3组均给予常规西医治疗,A组给予穴位贴敷治疗,B组给予益气通络、健脾补肾方治疗,C组给予益气通络、健脾补肾法联合穴位贴敷治疗。3组均持续治疗9个月。比较治疗9个月后的临床疗效,治疗前、治疗9个月后的6min步行距离(6 min walking distance,6MWD)、劳累程度、生活质量、呼吸困难指数、血气指标及炎性因子。结果治疗9个月后,C组总有效率为88.33%(53/60),高于A、B组的55.00%(33/60)、73.00%(44/60),B组高于A组(P<0.05)。与治疗前比较,治疗9个月后,3组6 MWD均延长,且C组长于A、B组,B组长于A组;劳累评估量表(Borg)评分、慢阻肺患者评估测试(COPD patient assessment test,CAT)评分、改良英国医学研究会呼吸困难指数(modified British medical research council,mMRC)、动脉血二氧化碳分压(PaCO_(2))、血清白细胞介素-8(interleukin-8,IL-8)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)及C反应蛋白(C-reactive protei,CRP)水平均降低,且C组低于A、B组,B组低于A组;3组血氧饱和度(SpO_(2))、动脉血氧分压(PaO_(2))均升高,且C组高于A、B组,B组高于A组(P<0.05),而3组酸碱度(pH)治疗前后及组间比较,差异无统计学差异(P>0.05)。结论益气通络、健脾补肾法联合穴位贴敷可有效缓解慢阻肺稳定期患者呼吸困难症状,减轻患者劳累程度及炎症反应,并改善患者血气指标,提高患者步行能力及生活质量,进而提高治疗效果。展开更多
目的:探讨补肾健脾活血方对过表达分泌型卷曲相关蛋白1(secreted frizzled related protein 1,SFRP1)、沉默SFRP1的UMR106细胞成骨分化及雌激素受体α(estrogen receptorα,ERα)的影响。方法:通过构建SFRP1过表达及沉默重组腺病毒载体...目的:探讨补肾健脾活血方对过表达分泌型卷曲相关蛋白1(secreted frizzled related protein 1,SFRP1)、沉默SFRP1的UMR106细胞成骨分化及雌激素受体α(estrogen receptorα,ERα)的影响。方法:通过构建SFRP1过表达及沉默重组腺病毒载体,并转染大鼠类成骨细胞系UMR106细胞,初步分为空载腺病毒组、过表达SFRP1组、沉默SFRP1组,并根据含药血清和生理盐水(空白)血清干预的不同分为6组,观察6组细胞的碱性磷酸酶(alkaline phosphatase,ALP)活性及细胞ERα蛋白表达情况。结果:含药血清干预的空载腺病毒组、SFRP1沉默组及SFRP1过表达组72 h后UMR106细胞ALP活性和ERα蛋白表达均高于空白血清干预的空载腺病毒组、SFRP1沉默组及SFRP1过表达组(P<0.05);空白血清+SFRP1沉默组的UMR106细胞ALP活性及ERα蛋白表达高于空白血清+空载腺病毒组(P<0.05),而空白血清+SFRP1过表达组的UMR106细胞ALP活性及ERα蛋白表达低于空白血清+空载腺病毒组(P<0.05)。结论:过表达SFRP1可以抑制UMR106细胞成骨分化,并下调ERα蛋白表达;沉默SFRP1和补肾健脾活血方均可促进UMR106细胞成骨分化,并上调ERα蛋白表达,且两者共同干预时作用更显著,说明补肾健脾活血方能够抑制SFRP1表达,而SFRP1并不是补肾健脾活血方调节成骨细胞代谢,提高成骨分化活性和促进ERα蛋白表达的唯一靶点,可能存在其他靶点共同促进调节成骨细胞代谢。展开更多
Introduction:This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney,lung,and spleen(TKLS)combined with Western medicine for stable chronic obstructive pulmonary disease(COPD).Materials ...Introduction:This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney,lung,and spleen(TKLS)combined with Western medicine for stable chronic obstructive pulmonary disease(COPD).Materials and Methods:Randomized controlled trials(RCTs)of TKLS for stable COPD were searched from four databases including Pub Med,the Cochrane Library,China Biology Medicine,and China National Knowledge Infrastructure from inception to December 2017.Two reviewers independently screened the literature,extracted the data,and assessed the risk of bias in the included studies.Rev Man5.3 software was used for meta-analysis.Results:Fourteen RCTs involving 1339 patients with stable COPD were included.Five of the included articles described the specific method of randomization,1 of them was double-blind method research,and 1 of them was single-blind method research.Compared with the conventional Western medicine(CWM)group,the use of TKLS,if combined with CWM demonstrated significantly improved effective rate(relative risk=1.25,95%confidence interval[CI]:1.18–1.33,P<0.00001),decreased traditional Chinese medicine syndrome score(mean difference[MD]-5.72,95%CI:-8.31 to-3.14,P<0.0001),Decreased St George's Respiratory Questionnaire total score(MD-7.39,95%CI:-10.46 to-4.31,P<0.00001),increased 6-min walk distance in meters(MD 78.46,95%CI:60.18–96.73,P<0.00001),increased forced expiratory volume 1%(MD 6.49,95%CI:3.64–9.33,P<0.00001),increased CD4(MD 9.84,95%CI:6.73–12.94,P<0.00001),CD8(MD-1.84,95%CI:-3.62 to-0.06,P=0.04)and CD4/CD8(MD 0.26,95%CI:0.20–0.32,P<0.0001),and increased immunoglobulin M(MD 0.15,95%CI:0.10–0.20 P<0.00001)..Conclusions:For stable COPD,TKLS combined with CWM is superior to CWM alone with regard to clinical effectiveness,symptoms,and quality of life.The above conclusion needs to be validated by further well-designed,multicentric,large-scale,double-blinded RCTs.展开更多
目的探讨补肾健脾药方联合FOLFOX化疗方案治疗脾肾阳虚型大肠癌患者的临床疗效。方法选取2019年8月—2021年8月期间昆明市中医医院收治的辨证为脾肾阳虚型的中晚期大肠癌患者92例,按随机数字表法分为对照组和治疗组,每组各46例。对照组...目的探讨补肾健脾药方联合FOLFOX化疗方案治疗脾肾阳虚型大肠癌患者的临床疗效。方法选取2019年8月—2021年8月期间昆明市中医医院收治的辨证为脾肾阳虚型的中晚期大肠癌患者92例,按随机数字表法分为对照组和治疗组,每组各46例。对照组接受单纯FOLFOX化疗方案治疗,治疗组患者接受FOLFOX化疗方案+健脾补肾法治疗,21 d为1个化疗周期。治疗3个周期后,观察比较两组患者临床疗效[疾病控制率(Disease control rate,DCR)]、化疗毒副作用发生及分级情况,治疗前后的中医症状积分、生活质量[生活质量问卷(Quality of life,QOL)、KPS评分量表(Karnofsky,KPS)]以及肿瘤标志物[血清癌胚抗原(Carcinoembryonic antigen,CEA)以及血清糖类抗原199(Carbohydrate antigen199,CA199)]水平。结果治疗后治疗组DCR为93.33%(42/45)明显高于对照组75.00%(33/44),差异有统计学意义(P<0.05)。治疗后两组患者中医症状积分较治疗前降低,差异有统计学意义(P<0.05);且治疗组中医症状积分较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者QOL、KPS评分均较治疗前升高,差异有统计学意义(P<0.05);且治疗组QOL、KPS评分均较对照组明显升高,差异有统计学意义(P<0.05)。治疗后两组患者血清CEA、CA199水平均较治疗前降低,差异有统计学意义(P<0.05);且治疗组血清CEA、CA199水平均较对照组明显降低,差异有统计学意义(P<0.05)。治疗期间,两组患者均未出现Ⅳ级程度的毒副作用。两组患者分级进行比较结果显示,对照组在恶心呕吐、腹泻这两项的反应剧烈程度高于治疗组,差异有统计学意义(P<0.05);两组患者在白细胞减少、血小板降低、转氨酶升高以及肌酐升高方面比较,差异无统计学意义(P>0.05)。结论FOLFOX化疗方案联合健脾补肾法治疗在改善中晚期大肠癌患者症状表现、生活质量,降低血清肿瘤标志物水平等方面更具优势,疗效佳,且能够降低化疗导致的胃肠道反应的剧烈程度,是治疗中晚期大肠癌的有效方案。展开更多
基金Inheritance and innovation of traditional Chinese Medicine"Ten million"talent project(Qihuang project)(No.2019-QTL-003)。
文摘Objective:To systematically evaluate the efficacy and safety of traditional Chinese medicine for regulating spleen and kidney.Methods:We developed a search strategy and then retrieved the database including CNKI,Wanfang data knowledge service platform,VIP journals resource integration service platform,PubMed,Embasefor randomized controlled trial of regulating spleen and kidney traditional Chinese medicine compared with conventional western medicine in the treatment of chronic uric acid nephropathy.The search deadline was set to June 30,2020.For the included literature,we applied the cochrane collaboration network risk bias assessment tool to evaluate the methodological quality,and evaluated the level of evidence according to GRADE standards.Quantitative data was analyzed by RevMan5.3 software,and trial sequential analysis method was used to analyze its efficiency.Results:A total of 709 cases in 10 articles were included.Compared with the control group,the related traditional Chinese medicine group improved the effective rate[RR=1.45,95%CI(1.32,1.58)],reduced the level of UA[MD=-36.24,95%CI(-41.03,-31.45)],BUN[SMD=-1.27,95%CI(-1.47,-1.07)]and SCR[MD=-36.33,95%CI(-55.79,-16.87),P=0.0003],the difference between the two groups was statistically significant(P<0.05).There was no evidence that a significant adverse reaction occurred.The results of TSA analysis showed that the Chinese medicine group had definite evidence for improving the efficiency.According to the GRADE evaluation criteria,the efficiency,UA,BUN and SCR outcome indicators were extremely low-quality evidence.Conclusions:Traditional Chinese medicine for regulating spleen and kidney in the treatment of chronic uric acid nephropathy improved efficiency,reduced the level of UA,BUN,SCR.Meanwhile,the therapy was proved to be safe.Nevertheless,the conclusions need further high-quality evidence to support.
基金TCM science and Technology project of Hebei Provincial Administration of Traditional Chinese Medicine in 2021(No.2021352):The therapeutic effect of cubital tunnel expansion plasty combined with Huangqi Guizhi Wuwu Decoction on cubital tunnel syndrome。
文摘Cubital tunnel syndrome is a disease in which ulnar nerve is compressed by its surrounding tissues,and its main clinical manifestations are pain,sensory disturbance and dyskinesia.Its incidence rate is the second highest among peripheral nerve entrapment diseases,and it is one of the common clinical diseases.The theory of liver,spleen and kidney can guide the treatment of cubital tunnel syndrome with traditional Chinese medicine and acupuncture.By discussing the traditional Chinese medicine(TCM)pathogenesis and treatment principles of cubital tunnel syndrome,it provides modern medical theoretical support for TCM treatment of cubital tunnel syndrome.
文摘Objective: To observe the acting pattern on the immune system by Kidney tonifying (KT) drugs. Methods: Three composite recipes were used on the 7- and 14-day corticosterone rat model to study the effect of recipes on the different patterns of immuno-modulatory and neuro- endocrinological systems. Results:The immune system of Spleen Invigorating(SI) group was well protected in either 7- or 14-day experiments,with the SI recipe showing no effect on the neuroendocrine system. It suggested that SI recipe might have direct action on immune system. On the other hand, KT group with no effect on neuroendocrine-immune (NEI) system in 7-day experiment, but showed a remarkable protective effect of the whole NEI system in 14-day experiment. Conclusion: The results indicated that KT recipe acts on the neuroendocrine system first, and then influence the immune system. It means that the action took place through down pathway of NEI network.
文摘目的探讨益气通络、健脾补肾法联合穴位贴敷在慢性阻塞性肺疾病(简称慢阻肺)稳定期患者中的应用效果。方法采用随机数字表法将于2020年1月—2021年12月在河北省张家口市中医院接受治疗的180例慢阻肺稳定期患者分为A组、B组和C组,各60例。3组均给予常规西医治疗,A组给予穴位贴敷治疗,B组给予益气通络、健脾补肾方治疗,C组给予益气通络、健脾补肾法联合穴位贴敷治疗。3组均持续治疗9个月。比较治疗9个月后的临床疗效,治疗前、治疗9个月后的6min步行距离(6 min walking distance,6MWD)、劳累程度、生活质量、呼吸困难指数、血气指标及炎性因子。结果治疗9个月后,C组总有效率为88.33%(53/60),高于A、B组的55.00%(33/60)、73.00%(44/60),B组高于A组(P<0.05)。与治疗前比较,治疗9个月后,3组6 MWD均延长,且C组长于A、B组,B组长于A组;劳累评估量表(Borg)评分、慢阻肺患者评估测试(COPD patient assessment test,CAT)评分、改良英国医学研究会呼吸困难指数(modified British medical research council,mMRC)、动脉血二氧化碳分压(PaCO_(2))、血清白细胞介素-8(interleukin-8,IL-8)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)及C反应蛋白(C-reactive protei,CRP)水平均降低,且C组低于A、B组,B组低于A组;3组血氧饱和度(SpO_(2))、动脉血氧分压(PaO_(2))均升高,且C组高于A、B组,B组高于A组(P<0.05),而3组酸碱度(pH)治疗前后及组间比较,差异无统计学差异(P>0.05)。结论益气通络、健脾补肾法联合穴位贴敷可有效缓解慢阻肺稳定期患者呼吸困难症状,减轻患者劳累程度及炎症反应,并改善患者血气指标,提高患者步行能力及生活质量,进而提高治疗效果。
文摘目的:探讨补肾健脾活血方对过表达分泌型卷曲相关蛋白1(secreted frizzled related protein 1,SFRP1)、沉默SFRP1的UMR106细胞成骨分化及雌激素受体α(estrogen receptorα,ERα)的影响。方法:通过构建SFRP1过表达及沉默重组腺病毒载体,并转染大鼠类成骨细胞系UMR106细胞,初步分为空载腺病毒组、过表达SFRP1组、沉默SFRP1组,并根据含药血清和生理盐水(空白)血清干预的不同分为6组,观察6组细胞的碱性磷酸酶(alkaline phosphatase,ALP)活性及细胞ERα蛋白表达情况。结果:含药血清干预的空载腺病毒组、SFRP1沉默组及SFRP1过表达组72 h后UMR106细胞ALP活性和ERα蛋白表达均高于空白血清干预的空载腺病毒组、SFRP1沉默组及SFRP1过表达组(P<0.05);空白血清+SFRP1沉默组的UMR106细胞ALP活性及ERα蛋白表达高于空白血清+空载腺病毒组(P<0.05),而空白血清+SFRP1过表达组的UMR106细胞ALP活性及ERα蛋白表达低于空白血清+空载腺病毒组(P<0.05)。结论:过表达SFRP1可以抑制UMR106细胞成骨分化,并下调ERα蛋白表达;沉默SFRP1和补肾健脾活血方均可促进UMR106细胞成骨分化,并上调ERα蛋白表达,且两者共同干预时作用更显著,说明补肾健脾活血方能够抑制SFRP1表达,而SFRP1并不是补肾健脾活血方调节成骨细胞代谢,提高成骨分化活性和促进ERα蛋白表达的唯一靶点,可能存在其他靶点共同促进调节成骨细胞代谢。
基金supported by the National Natural Science Foundation of China (no. 81760901)
文摘Introduction:This study aimed to evaluate the clinical effectiveness and safety of tonifying kidney,lung,and spleen(TKLS)combined with Western medicine for stable chronic obstructive pulmonary disease(COPD).Materials and Methods:Randomized controlled trials(RCTs)of TKLS for stable COPD were searched from four databases including Pub Med,the Cochrane Library,China Biology Medicine,and China National Knowledge Infrastructure from inception to December 2017.Two reviewers independently screened the literature,extracted the data,and assessed the risk of bias in the included studies.Rev Man5.3 software was used for meta-analysis.Results:Fourteen RCTs involving 1339 patients with stable COPD were included.Five of the included articles described the specific method of randomization,1 of them was double-blind method research,and 1 of them was single-blind method research.Compared with the conventional Western medicine(CWM)group,the use of TKLS,if combined with CWM demonstrated significantly improved effective rate(relative risk=1.25,95%confidence interval[CI]:1.18–1.33,P<0.00001),decreased traditional Chinese medicine syndrome score(mean difference[MD]-5.72,95%CI:-8.31 to-3.14,P<0.0001),Decreased St George's Respiratory Questionnaire total score(MD-7.39,95%CI:-10.46 to-4.31,P<0.00001),increased 6-min walk distance in meters(MD 78.46,95%CI:60.18–96.73,P<0.00001),increased forced expiratory volume 1%(MD 6.49,95%CI:3.64–9.33,P<0.00001),increased CD4(MD 9.84,95%CI:6.73–12.94,P<0.00001),CD8(MD-1.84,95%CI:-3.62 to-0.06,P=0.04)and CD4/CD8(MD 0.26,95%CI:0.20–0.32,P<0.0001),and increased immunoglobulin M(MD 0.15,95%CI:0.10–0.20 P<0.00001)..Conclusions:For stable COPD,TKLS combined with CWM is superior to CWM alone with regard to clinical effectiveness,symptoms,and quality of life.The above conclusion needs to be validated by further well-designed,multicentric,large-scale,double-blinded RCTs.
文摘目的探讨补肾健脾药方联合FOLFOX化疗方案治疗脾肾阳虚型大肠癌患者的临床疗效。方法选取2019年8月—2021年8月期间昆明市中医医院收治的辨证为脾肾阳虚型的中晚期大肠癌患者92例,按随机数字表法分为对照组和治疗组,每组各46例。对照组接受单纯FOLFOX化疗方案治疗,治疗组患者接受FOLFOX化疗方案+健脾补肾法治疗,21 d为1个化疗周期。治疗3个周期后,观察比较两组患者临床疗效[疾病控制率(Disease control rate,DCR)]、化疗毒副作用发生及分级情况,治疗前后的中医症状积分、生活质量[生活质量问卷(Quality of life,QOL)、KPS评分量表(Karnofsky,KPS)]以及肿瘤标志物[血清癌胚抗原(Carcinoembryonic antigen,CEA)以及血清糖类抗原199(Carbohydrate antigen199,CA199)]水平。结果治疗后治疗组DCR为93.33%(42/45)明显高于对照组75.00%(33/44),差异有统计学意义(P<0.05)。治疗后两组患者中医症状积分较治疗前降低,差异有统计学意义(P<0.05);且治疗组中医症状积分较对照组明显降低,差异有统计学意义(P<0.05)。治疗后两组患者QOL、KPS评分均较治疗前升高,差异有统计学意义(P<0.05);且治疗组QOL、KPS评分均较对照组明显升高,差异有统计学意义(P<0.05)。治疗后两组患者血清CEA、CA199水平均较治疗前降低,差异有统计学意义(P<0.05);且治疗组血清CEA、CA199水平均较对照组明显降低,差异有统计学意义(P<0.05)。治疗期间,两组患者均未出现Ⅳ级程度的毒副作用。两组患者分级进行比较结果显示,对照组在恶心呕吐、腹泻这两项的反应剧烈程度高于治疗组,差异有统计学意义(P<0.05);两组患者在白细胞减少、血小板降低、转氨酶升高以及肌酐升高方面比较,差异无统计学意义(P>0.05)。结论FOLFOX化疗方案联合健脾补肾法治疗在改善中晚期大肠癌患者症状表现、生活质量,降低血清肿瘤标志物水平等方面更具优势,疗效佳,且能够降低化疗导致的胃肠道反应的剧烈程度,是治疗中晚期大肠癌的有效方案。
